Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health
Meta-Analysis |
Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia
From the Section of Gerontology and Geriatrics, Department of General Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
The authors performed a systematic review to summarize the epidemiologic evidence on the association between use of nonsteroidal antiinflammatory drugs (NSAIDs) and the risk of dementia. A total of 25 case-control and cohort studies that reported an odds ratio/relative risk were included. Study-specific log relative risks were weighted by the inverse of their variances to obtain pooled relative risks and 95% confidence intervals. The authors divided the reports into studies with prevalent dementia cases, studies with incident dementia cases, and studies where cognitive decline was used as the clinical endpoint. The pooled relative risks of the three groups of studies were 0.51 (95% confidence interval (CI): 0.37, 0.70), 0.79 (95% CI: 0.68, 0.92), and 1.23 (95% CI: 0.70, 2.31), respectively. Within these subgroups, heterogeneity was present only in the studies with prevalent cases (p = 0.001). Because the benefit of NSAIDs in preventing dementia or cognitive impairment was 50% in studies with prevalent dementia cases, declined to 20% in studies with incident dementia cases, and was absent in studies where cognitive decline was used as the endpoint, the authors conclude that most of the reported beneficial effects of NSAIDs may result from various forms of bias: recall bias, prescription bias, and publication bias.
Alzheimer disease; anti-inflammatory agents, non-steroidal; dementia; meta-analysis
Abbreviations: CI, confidence interval; NSAID(s), nonsteroidal antiinflammatory drug(s).
Correspondence to Dr. A. J. M. de Craen, Section of Gerontology and Geriatrics, C2-R, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, the Netherlands (e-mail: craen{at}lumc.nl).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology, May 6, 2008; 70(19): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Anstey, D. M. Lipnicki, and L.-F. Low Cholesterol as a Risk Factor for Dementia and Cognitive Decline: A Systematic Review of Prospective Studies With Meta-Analysis Am J Geriatr Psychiatry, May 1, 2008; 16(5): 343 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patterson MD, J. W. Feightner MD MSc, A. Garcia MD PhD, G.-Y. R. Hsiung MD MHSc, C. MacKnight MD MSc, and A. D. Sadovnick PhD Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease Can. Med. Assoc. J., February 26, 2008; 178(5): 548 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Anstey, C. von Sanden, A. Salim, and R. O'Kearney Smoking as a Risk Factor for Dementia and Cognitive Decline: A Meta-Analysis of Prospective Studies Am. J. Epidemiol., August 15, 2007; 166(4): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Kang, N. Cook, J. Manson, J. E Buring, and F. Grodstein Low dose aspirin and cognitive function in the women's health study cognitive cohort BMJ, May 12, 2007; 334(7601): 987 - 987. [Abstract] [Full Text] [PDF]
|
|